ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novo Nordisk has agreed to acquire Calibrium and MB2, two diabetes-related start-ups cofounded by Richard DiMarchi, a chemistry professor at Indiana University. Founded in 2013, Calibrium is developing novel peptides for the treatment of diabetes and related metabolic diseases. MB2, founded a year later, is advancing a pipeline of mixed agonist drugs for diabetes and obesity. Earlier in his career, DiMarchi was an Eli Lilly & Co. R&D executive involved in discovering the diabetes drugs Humulin and Humalog.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X